Unnatural Amino Acids Market to Reach $2.39 Billion by 2031 as Peptide Therapeutics and Biopharmaceutical Research Accelerate

Unnatural Amino Acids Market to Reach $2.39 Billion by 2031 as Peptide Therapeutics and Biopharmaceutical Research Accelerate Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The "Unnatural Amino Acids - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global unnatural amino acids market is projected to increase from USD 1.45 billion in 2025 and USD 1.58 billion in 2026 to USD 2.39 billion by 2031, registering a compound annual growth rate of 8.70% from 2026 to 2031. Market expansion is being supported by growing peptide therapeutic pipelines, increased pharmaceutical and biopharmaceutical research expenditure, advances in protein engineering, and rising demand for high-purity building blocks used in drug discovery and commercial manufacturing.

The market report provides forecasts by product type, application, end user, synthesis technology, and geography. Product categories include D-amino acids, non-proteinogenic amino acids, peptidomimetics, and other specialized products. Key applications span pharmaceuticals, biotechnology, the chemical industry, food and beverage, and additional research and industrial uses.

Peptide Therapeutics Drive Unnatural Amino Acids Market Growth

The rapid development of peptide therapeutics, including GLP-1 receptor agonists, cyclic peptides, antibody-drug conjugates, peptide-drug conjugates, and stapled peptide candidates, is creating sustained demand for protected and modified amino acid building blocks. Pharmaceutical developers increasingly use unnatural residues to improve molecular stability, extend half-life, enhance protease resistance, and optimize therapeutic performance.

Continued regulatory and commercial activity in metabolic disease is expected to encourage further investment in next-generation peptide programs. Oral delivery research and competition from non-peptidic GLP-1 candidates are also prompting developers to pursue improved peptide designs with stronger stability and pharmacokinetic characteristics.

Genetic code expansion technologies represent another important growth opportunity. Advances in rare codon recoding, programmable RNA editing, and site-specific incorporation methods are increasing the number and variety of non-canonical amino acids that can be introduced into proteins. These developments support protein engineering, precision conjugation, diagnostics, and biopharmaceutical research while strengthening demand for suppliers that can provide consistent quality, analytical documentation, and scalable manufacturing.

Production Costs and Scale-Up Remain Key Market Constraints

High production costs continue to restrict broader adoption of pharmaceutical-grade protected residues. Chemical synthesis requires specialized reactors, chiral chemistry capabilities, purification systems, and solvent recovery infrastructure. These requirements increase capital expenditure and make rapid scale-up challenging, particularly for novel residues produced in limited volumes.

Enzymatic synthesis offers potential cost and sustainability advantages, with multi-enzyme cascade technologies demonstrating progress in the production of non-canonical amino acids. However, purity, process validation, regulatory compliance, and good manufacturing practice requirements continue to limit the immediate replacement of established chemical synthesis routes. Stringent regulatory standards for novel drug substances also create barriers for suppliers seeking to participate in high-value commercial contracts.

Segment Analysis

Non-proteinogenic amino acids are projected to represent 38.60% of market revenue by product type in 2025. Their leading position reflects broad use across oncology, metabolic disease, infectious disease, chemical biology, and advanced drug development. The category includes beta amino acids, N-methylated residues, phosphorylated analogs, and ring-constrained variants.

D-amino acids remain strategically important for improving resistance to protease degradation and supporting longer-lasting therapeutic activity. Peptidomimetics are forecast to record the fastest product growth, advancing at a CAGR of 11.45% through 2031. Growth will be supported by their stability, oral delivery potential, and ability to address complex protein-protein interaction targets.

Pharmaceutical applications are expected to account for 43.80% of the unnatural amino acids market in 2025. Demand is concentrated in peptide active pharmaceutical ingredients, GLP-1 analogs, conjugate linkers, cyclic peptides, and other regulated drug programs. Biotechnology is expected to remain the second-largest application, driven by recombinant protein engineering, advanced cell culture formulations, and site-specific protein modification. Food and beverage applications are projected to grow at a CAGR of 10.67% through 2031.

Primary end users include pharmaceutical companies, biotechnology companies, academic and research institutes, contract development and manufacturing organizations, and diagnostic and reagent manufacturers. The analysis covers chemical synthesis, enzymatic synthesis, and other emerging production technologies.

Regional Market Outlook

North America is projected to hold 43.30% of the global unnatural amino acids market in 2025. The region benefits from extensive peptide drug development, established biotechnology clusters, strong pharmaceutical research investment, and significant demand for research-grade, clinical-grade, and commercial-scale materials. The United States remains the region's principal market, supported by GLP-1 research, antibody-drug conjugate development, peptide API manufacturing, and advanced protein engineering.

Europe is expected to remain the second-largest regional market. Germany, the United Kingdom, France, Italy, and Spain form the principal demand base, supported by pharmaceutical manufacturing, specialty chemical production, and chemical biology research. Continued investment in peptide manufacturing capacity is reinforcing Europe's role in the global supply chain, while strict regulatory requirements favor qualified suppliers with robust compliance systems.

Asia-Pacific is forecast to expand at an 11.56% CAGR through 2031, making it the fastest-growing region. Rising peptide and conjugate development, expanding contract manufacturing capacity, increasing domestic research activity, and a broadening base of custom synthesis providers are supporting regional growth. China, India, Japan, South Korea, and Australia are expected to generate significant opportunities. South America and the Middle East and Africa remain smaller markets but offer medium-term potential as healthcare investment and biopharmaceutical capacity increase.

Key Topics Covered

1 INTRODUCTION

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

4.1 Market Drivers

4.1.1 Surge in Peptide Therapeutics Pipeline and FDA Approvals (Including GLP-1 Receptor Agonist Analogs and Cyclic Peptides)

4.1.2 Expansion of Genetic Code Expansion (GCE) Technologies for Site-Specific Protein Modification

4.1.3 Rising Adoption in Antibody-Drug Conjugate (ADC) and Peptide-Drug Conjugate (PDC) Development

4.1.4 Increasing Global Pharmaceutical and Biopharmaceutical R&D Expenditure

4.1.5 Growth of CDMO Outsourcing for Custom UAA Synthesis Across Scales

4.1.6 Demand for Protease-Resistant and Metabolically Stable Therapeutic Peptides

4.2 Market Restraints

4.2.1 High Cost of Chemical Synthesis and Challenges in Production Scale-Up

4.2.2 Stringent Regulatory and GMP Requirements for Novel UAA-Containing Drug Substances

4.2.3 Limited Commercial Supplier Base for Specialized Non-Standard Amino Acids

4.2.4 Incorporation Efficiency Limitations in Cell-Based Genetic Code Expansion Systems

4.3 Value and Supply Chain Analysis

4.4 Regulatory Landscape

4.5 Technological Outlook

4.6 Porter's Five Forces Analysis

4.6.1 Bargaining Power of Suppliers

4.6.2 Bargaining Power of Buyers

4.6.3 Threat of New Entrants

4.6.4 Threat of Substitutes

4.6.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

5.1 By Product Type

5.1.1 D-Amino Acids

5.1.2 Non-proteinogenic Amino Acids

5.1.3 Peptidomimetics

5.1.4 Other Product Types

5.2 By Application

5.2.1 Pharmaceuticals

5.2.2 Biotechnology

5.2.3 Chemical Industry

5.2.4 Food and Beverage

5.2.5 Other Applications

5.3 By End User

5.3.1 Pharmaceutical Companies

5.3.2 Biotechnology Companies

5.3.3 Academic and Research Institutes

5.3.4 Contract Development and Manufacturing Organizations

5.3.5 Diagnostic and Reagent Manufacturers

5.4 By Synthesis Technology

5.4.1 Chemical Synthesis

5.4.2 Enzymatic Synthesis

5.4.3 Other Synthesis Methods

5.5 By Geography

5.5.1 North America

5.5.1.1 United States

5.5.1.2 Canada

5.5.1.3 Mexico

5.5.2 Europe

5.5.2.1 Germany

5.5.2.2 United Kingdom

5.5.2.3 France

5.5.2.4 Italy

5.5.2.5 Spain

5.5.2.6 Rest of Europe

5.5.3 Asia-Pacific

5.5.3.1 China

5.5.3.2 India

5.5.3.3 Japan

5.5.3.4 Australia

5.5.3.5 South Korea

5.5.3.6 Rest of Asia-Pacific

5.5.4 Middle East and Africa

5.5.4.1 GCC

5.5.4.2 South Africa

5.5.4.3 Rest of Middle East and Africa

5.5.5 South America

5.5.5.1 Brazil

5.5.5.2 Argentina

5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)

6.3.1 Ajinomoto Co., Inc.

6.3.2 Ambeed, Inc.

6.3.3 AnaSpec, Inc.

6.3.4 Bachem Holding AG

6.3.5 BOC Sciences

6.3.6 Chem-Impex International, Inc.

6.3.7 CordenPharma International

6.3.8 Creative Peptides

6.3.9 CSBio

6.3.10 GL Biochem (Shanghai) Ltd.

6.3.11 Iris Biotech GmbH

6.3.12 Merck KGaA

6.3.13 New England Peptide, Inc.

6.3.14 Peptides International, Inc.

6.3.15 PolyPeptide Group AG

6.3.16 Senn Chemicals AG

6.3.17 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

7.1 White Space and Unmet Need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/5jvldy

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.